WHO ICTRP trial
Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy…
ChiCTR2600116934 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2600116934 |
|---|---|
| Public title | Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular |
| Scientific title | Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular |
| Primary sponsor | Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital &Institute) |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | Hepatocellular |
| Interventions | Trial group:Sintilimab 200mg Q3W for 2 cycles + stereotactic radiotherapy 8Gy*3 fractions on D1, D3, D5, followed by adjuvant sintilimab 200mg Q3W for up to one year postoperatively.;Control group:Surgery followed by adjuvant sintilimab… |
| Registration date | Jan 16, 2026 |
| Target size | Trial group:55;Control group:55 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: